CIA
DFTX icon

Concurrent Investment Advisors’s Definium Therapeutics DFTX Stock Holding History

Concurrent Investment Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$943K Sell
20,044
-1,241
-6% -$30.7K 0.01% 1037
2026
Q1 		$402K Buy
21,285
+888
+4% +$15.1K ﹤0.01% 1320
2025
Q4 		$273K Buy
+20,397
New +$252K ﹤0.01% 1461

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Concurrent Investment Advisors's DFTX Position: Q2 2026 in Review

Concurrent Investment Advisors reduced its Definium Therapeutics (DFTX) stake by 5.8% in Q2 2026, selling an estimated $30.7K and leaving 20,044 shares worth $943K. The position accounts for 0.01% of the portfolio, ranked #1037.

Concurrent Investment Advisors first reported a position in DFTX in Q4 2025 and has held it in 3 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Concurrent Investment Advisors held 20,044 shares of Definium Therapeutics worth $943K as of Q2 2026.
  • Concurrent Investment Advisors sold 1,241 Definium Therapeutics shares in Q2 2026, an estimated $30.7K.
  • Definium Therapeutics made up 0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #1037 holding.
  • Concurrent Investment Advisors first reported a position in Definium Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.